Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
JBT-101 in Systemic Lupus Erythematosus (SLE)
NCT03093402 · View on ClinicalTrials.gov ↗
Study Summary
The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE). * One hundred adults with active joint disease and at least moderate pain will be enrolled in this study to evaluate treatment of their systemic lupus erythematosus (SLE) with JBT-101. JBT-101 is a synthetic endocannabinoid receptor type 2 (CB2) agonist and an activator of the body's normal processes, to resolve innate immune responses without immunosuppression. * Participants will receive 2 doses of JBT-101 by mouth (three groups of varying doses) or, placebo, for 84 days and will continue to be followed for an additional 28 days. Participant visits to assess endpoints occur on Day 1, then every 2 weeks twice, then every 4 weeks three times, for a total of six visits. * The change in maximum daily pain Numerical Rating Scale (NRS) score from Baseline (Visit 1) will be assessed at every visit.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JBT-101
Study Locations (16)
New York
- Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases — Manhasset
- New York University Langone Medical Center: Department of Medicine, Division of Rheumatology — New York
- Columbia University Medical Center: Department of Medicine, Division of Rheumatology — New York
- Bronx-Lebanon Hospital Center: Division of Rheumatology — The Bronx
Pennsylvania
- Penn State MS Hershey Medical Center — Hershey
- University of Pennsylvania — Philadelphia
- Temple University — Philadelphia
- University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology — Pittsburgh
California
- University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology — La Jolla
- UCLA Medical Center: Division of Rheumatology — Los Angeles
- University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center — San Francisco
Connecticut
- Yale University — New Haven
Georgia
- Emory University: Division of Rheumatology — Atlanta
North Carolina
- Duke University — Durham
Ohio
- MetroHealth Medical Center — Cleveland
South Carolina
- Medical University of South Carolina — Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2017-12-21 |
| Est. Completion | 2021-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03093402
The ClinicalTrials.gov registry entry for NCT03093402 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03093402 reports 16 study locations spanning 8 distinct geographic areas — top geographies include New York, Pennsylvania, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03093402 about?
NCT03093402 is a clinical study titled "JBT-101 in Systemic Lupus Erythematosus (SLE)". The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE). * One hundred adults with active joint disease and at least moderate pain will be enrolled in this study to evaluate treatment of their syste...
What is the current status of trial NCT03093402?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2017-12-21. Estimated completion is 2021-07-28.
What conditions does trial NCT03093402 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Lupus, SLE. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03093402?
The interventions under investigation include: Placebo (DRUG), JBT-101 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03093402?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03093402 being conducted?
This trial has 16 study locations across California, Connecticut, Georgia, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.